The future of epigenetic therapy in solid tumours--lessons from the past.
TLDR
It is hypothesized that in using low-dose epigenetic-modulating agents, tumour cells can be reprogrammed, which overrides any immediate cytotoxic and off-target effect observed at high dose, and could give these agents a prominent place in cancer management.Abstract:
The promise of targeting epigenetic abnormalities for cancer therapy has not been realized for solid tumours, although increasing evidence is demonstrating its worth in haematological malignancies. In fact, true clinical efficacy in haematopoietic-related neoplasms has only become evident at low doses of epigenetic-targeting drugs (namely, inhibitors of histone deacetylase and DNA methyltransferases). Describing data from preclinical studies and early clinical trial results, we hypothesize that in using low-dose epigenetic-modulating agents, tumour cells can be reprogrammed, which overrides any immediate cytotoxic and off-target effect observed at high dose. We suggest that such optimization of drug dosing and scheduling of currently available agents could give these agents a prominent place in cancer management--when used alone or in combination with other therapies. If so, optimal use of these known agents might also pave the way for the introduction of other agents that target the epigenome.read more
Citations
More filters
Journal ArticleDOI
Liquid Biopsies: Genotyping Circulating Tumor DNA
Luis A. Diaz,Alberto Bardelli +1 more
TL;DR: The ability to detect and quantify tumor mutations has proven effective in tracking tumor dynamics in real time as well as serving as a liquid biopsy that can be used for a variety of clinical and investigational applications not previously possible.
Journal ArticleDOI
Gene Body Methylation Can Alter Gene Expression and Is a Therapeutic Target in Cancer
Xiaojing Yang,Han Han,Daniel D. De Carvalho,Daniel D. De Carvalho,Fides D. Lay,Peter A. Jones,Gangning Liang +6 more
TL;DR: It is shown that 5-aza-2'-deoxycytidine treatment not only reactivates genes but decreases the overexpression of genes, many of which are involved in metabolic processes regulated by c-MYC.
Journal ArticleDOI
Targeting the cancer epigenome for therapy
TL;DR: As epigenetic drugs target the epigenome as a whole, these true 'genomic medicines' lessen the need for precision approaches to individualized therapies.
Journal ArticleDOI
Epigenetic Determinants of Cancer
Stephen B. Baylin,Peter A. Jones +1 more
TL;DR: Epigenetic therapies are one standard of care for a preleukemic disorder and form of lymphoma and the application of epigenetic therapies in the treatment of solid tumors is also emerging as a viable therapeutic route.
Journal ArticleDOI
Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
TL;DR: The possible role of epigenetic abnormalities as well as genetic alterations in such dynamics and in the creation of cellular heterogeneity in cancers of all types are discussed.
References
More filters
Journal ArticleDOI
Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy
Samir E. Witta,Robert M. Jotte,Katrik Konduri,Marcus A. Neubauer,Alexander I. Spira,Robert L. Ruxer,Marileila Varella-Garcia,Paul A. Bunn,Fred R. Hirsch +8 more
TL;DR: High E-cadherin expression levels at time of diagnosis indicate an increased sensitivity to HDACi/EGFR-TKI inhibition providing the basis for a biomarker-driven validation study.
Journal ArticleDOI
Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher‐risk myelodysplastic syndromes
Lewis R. Silverman,Pierre Fenaux,Ghulam J. Mufti,Valeria Santini,Eva Hellström-Lindberg,Norbert Gattermann,Guillermo Sanz,Alan F. List,Steven D. Gore,John F. Seymour +9 more
TL;DR: In the AZA‐001 trial, azacitidine (75 mg/m2/d subcutaneously for Days 1‐7 of every 28‐day cycle) demonstrated improved survival compared with conventional care regimens in patients with intermediate‐2‐ or high‐risk myelodysplastic syndrome and acute myeloid leukemia with 20% to 30% bone marrow blasts.
Journal ArticleDOI
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer
Siqing Fu,Wei Hu,Revathy B. Iyer,John J. Kavanagh,Robert L. Coleman,Charles F Levenback,Anil K. Sood,Judith K. Wolf,David M. Gershenson,Maurie Markman,Bryan T. Hennessy,Razelle Kurzrock,Robert C. Bast +12 more
TL;DR: A phase 1b‐2a clinical trial of this sequential combination of azacitidine and carboplatin was initiated in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancer.
Journal ArticleDOI
The Emerging Therapeutic Potential of Histone Methyltransferase and Demethylase Inhibitors
TL;DR: An overview of the mechanisms of action of histone methyltransferases and demethylases, their role in the formation of certain diseases, and available inhibitors is given.
Journal ArticleDOI
Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors
Giuseppe Giaccone,Giuseppe Giaccone,Arun Rajan,Arun Rajan,Arlene Berman,Arlene Berman,Ronan J. Kelly,Ronan J. Kelly,Eva Szabo,Eva Szabo,Ariel Lopez-Chavez,Ariel Lopez-Chavez,Jane B. Trepel,Jane B. Trepel,Min-Jung Lee,Min-Jung Lee,Liang Cao,Liang Cao,Igor Espinoza-Delgado,Igor Espinoza-Delgado,John Spittler,John Spittler,Patrick J. Loehrer,Patrick J. Loehrer +23 more
TL;DR: Belinostat has modest antitumor activity in this group of heavily pretreated thymic malignancies, however, the duration of response and disease stabilization is intriguing, and additional testing of belinostat in this disease is warranted.
Related Papers (5)
A decade of exploring the cancer epigenome — biological and translational implications
Stephen B. Baylin,Peter A. Jones +1 more